Chargement en cours...
Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries
Apixaban (APX) is a direct inhibitor of factor X (FXa) approved for prophylaxis and treatment of deep venous thrombosis and atrial fibrillation. Because FXa activates protease-activated receptor 2 (PAR-2) in endothelium and vascular smooth muscle, inhibition of FXa by APX may affect vasomotor functi...
Enregistré dans:
| Publié dans: | Front Pharmacol |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5513931/ https://ncbi.nlm.nih.gov/pubmed/28769809 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00480 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|